PP405: Is the “Baldness Cure” Real?
Every few years the internet decides the cure for baldness has arrived. Most times it’s vaporware. PP405 is different, and I say that as someone who’s professionally skeptical of hype. It has a genuinely novel mechanism and it posted real human numbers in 2025. It’s also not a cure, and calling it one sets you up to be disappointed. Let me walk the line honestly.
What makes PP405 actually new
Almost everything we use today fights hair loss by reducing damage. Finasteride lowers DHT. Minoxidil props open the growth phase. Both are defensive. PP405, developed by Pelage Pharmaceuticals out of work at UCLA, plays offense in a way nothing mainstream does: it tries to wake up follicles that have gone dormant.
The mechanism is the headline. In a thinning scalp, a lot of follicles aren’t dead, they’ve shrunk and gone quiet, with their stem cells stuck in a low-energy resting state. PP405 is a topical small molecule that inhibits something called the mitochondrial pyruvate carrier, which flips those stem cells into a more active metabolic mode and nudges them to start growing hair again.[1] In plain terms: instead of slowing the decline, it tries to restart the engine. That’s why people get excited, and the excitement isn’t baseless.
The 2025 data, with the real numbers
This is where PP405 earns a different grade than the usual cure-of-the-month. In mid-2025, Pelage reported Phase 2a results.[2] The trial enrolled 78 men and women with androgenetic alopecia, who applied a topical PP405 gel (a 0.05% formulation) once daily for four weeks, then were followed out to twelve. The standout figure: about 31% of treated patients showed a greater than 20% increase in hair density after roughly eight weeks. And importantly, the drug induced new hair from follicles where there hadn’t been visible hair before, which is the regenerative claim actually showing up in data.
The safety side looked clean too. It met its primary safety endpoint, and no PP405 was detectable in the bloodstream, meaning it acts locally without the systemic exposure that drives the hormonal-side-effect fears around finasteride. On the strength of this, Pelage has signaled a move toward Phase 3, though as of mid-2026 that trial is still being set up rather than recruiting.
“PP405 is the rare hair compound where the mechanism is genuinely novel and the early human numbers are real. That’s worth getting interested in. It still isn’t a cure, and twelve-week data isn’t a five-year track record.”
Why “cure” is the wrong word
I want to be the person who tells you the unsexy truth here. A 31% response rate at eight weeks is encouraging, but flip it around: most patients didn’t hit that threshold in that window. The follow-up was short. We don’t yet know how durable the growth is, whether you have to keep applying it forever, how it performs over years, or how it does in a large Phase 3 against placebo. Every one of those questions has killed promising hair compounds before. “Positive Phase 2a” is a real milestone and a long way from your bathroom shelf.
And the word cure implies you fix it once and you’re done. Nothing in the data suggests that. The honest framing is: a potentially powerful new tool that might, if Phase 3 holds up and regulators agree, join the lineup in a few years, probably as something you keep using. That’s genuinely exciting. It’s just not magic.
Correction: PP405 and JXL069 are the same molecule
Updated August 2026. An earlier version of this article said PP405 and JXL069 were different compounds. That was wrong, and I corrected it on the channel.
In July 2026 the World Health Organization published Proposed INN List 135, which assigned the name suvomipic and confirmed that PP-405 and JXL069 are one and the same molecule, CAS 2260696-63-5. So when I have been documenting JXL069 on myself, I have been documenting the same compound Pelage is developing as PP405. The trial data above belongs to Pelage’s formulation and its clinical programme, and that distinction still matters: a research-grade solution bought online is not the drug that was tested, at the dose it was tested, in the trial described here.
| Question | Honest answer (August 2026) |
|---|---|
| Is PP405 a cure? | No. It’s a promising regenerative drug in trials. |
| Can I buy it? | Not as an approved product. It’s investigational. |
| Does it have real human data? | Yes, a Phase 2a with measurable density gains. |
| Is JXL069 the same thing? | Yes, same molecule (suvomipic). Not the same tested formulation. |
| Would I stop my current treatment for it? | Absolutely not. Keep what works while this proves itself. |
My take
PP405 is the most legitimately interesting thing in hair loss right now, and I don’t say that lightly given how many “cures” I’ve watched evaporate. A new mechanism plus real Phase 2a numbers is a genuinely different signal than a press release. But interesting is not available, and Phase 2a is not Phase 3. If you’re losing hair today, the move isn’t to wait for PP405, it’s to protect what you have with proven treatments now and keep PP405 on your radar for when, and if, it crosses the finish line. Hope is not a treatment plan. The follicles you keep this year are.
I’m Philippe Boissard, a hair-loss and male-physiology researcher and author (M.Sc., Aalborg University). I published a comparative review of finasteride and dutasteride in androgenetic alopecia, openly available at doi.org/10.5281/zenodo.20507736. More of my work is at philippeb.pro.
This article discusses investigational and prescription treatments. Education, not medical advice.
References
- PP405 (overview of mechanism and development). Wikipedia, accessed 2026. en.wikipedia.org/wiki/PP405
- Pelage Pharmaceuticals Announces Positive Phase 2a Clinical Trial Results for PP405 in Regenerative Hair Loss Therapy. Pelage Pharmaceuticals, 2025. pelagepharma.com
- Pelage’s PP405 Demonstrates Efficacy in Phase 2a Trial for Androgenetic Alopecia. Dermatology Times, 2025. dermatologytimes.com
- Proposed INN List 135 (suvomipic). World Health Organization, July 2026.
Get my free hair-loss protocol
The exact evidence-based routine I actually use and recommend: what works, in what order, with no hype. Enter your email on the next page and I’ll send it straight to you.
